Abstracts tagged "Biomarkers"

Abstract Number: 0685 • ACR Convergence 2024
KL-6 and IL-18 Biomarkers in Systemic Sclerosis-associated Interstitial Lung Disease: Enhancing Prognostic Insights into Early Detection, Progression, Lung Volume Changes,and Mortality Risk
cristiana sieiro santos¹, Miriam Retuerto², Laura Sierra², Sara Calleja Antolín², Elena Bollo de Miguel², Jose Ordas Martínez³, Paula Pérez García², Pedro Baenas², Clara Moriano Morales², Javier de la Calle Lorenzo² and Elvira Díez Álvarez⁴, ¹Rheumatology Department, Complejo Asistencial Universitario de León, León, Spain, Leon, Spain, ²Complejo Asistencial Universitario de León, León, Spain, ³Complejo Asistencial Universitario de Leon, Leon, ⁴Complejo Asistencial Universitario de León, Leon, Spain
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in scleroderma, underscoring the critical demand for reliable biomarkers. KL-6 and IL-18, have been…
Abstract Number: 0811 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Longitudinal Serum Samples to Predict Treatment Response in Lupus Nephritis
Benjamin Jones¹, Rufei Lu², Andrea Fava³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steven Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Judith James¹³ and Joel Guthridge¹³, ¹Oklahoma State University, Oklahoma City, OK, ²University of California San Francisco, San Bruno, CA, ³Johns Hopkins University, Baltimore, MD, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Lupus nephritis (LN) can lead to severe morbidity and early mortality in SLE patients. While therapeutic options for LN have improved, they are not…
Abstract Number: 0915 • ACR Convergence 2024
APOH Locus Associated with Higher Anti-Beta-2-Glycoprotein 1 Antibody Levels Paradoxically Protects Against Venous Thromboembolism
Yiming Luo, Lili Liu, Atlas Khan, R. Graham Barr, Elana Bernstein and Krzysztof Kiryluk, Columbia University Irving Medical Center, New York, NY
Background/Purpose: Anti-Beta-2-glycoprotein 1 antibody (anti-B2GP1) is associated with antiphospholipid syndrome (APS), a rare autoimmune disease that causes venous thromboembolism (VTE). APOH, which expresses the B2GP1…
Abstract Number: 1268 • ACR Convergence 2024
Neutrophil Lymphocyte Ratio as a Novel Marker of Skin Disease Activity in Older Children with Juvenile Dermatomyositis
Shreya Swaminathan¹, Nidhi Naik², Susan Shenoi³, Sarah Vandenbergen⁴, Jessica Turnier⁵, Zilan Zheng⁶, Jessica Neely⁶, James Andrews⁷ and Christian Lood⁸, ¹University of Washington, Seattle, ²Seattle children's hospital, Bothell, WA, ³Seattle Children's Hospital and Research Center, Mercer Island, WA, WA, ⁴University of Michigan, Ann Arbor, MI, ⁵University of Michigan, Saline, MI, ⁶UCSF, San Francisco, CA, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸University of Washington, Seattle, WA
Background/Purpose: Exaggerated neutrophil activation can lead to inflammation and organ damage in rheumatic diseases, including dermatomyositis (DM). In both juvenile (JDM) and adult DM, markers…
Abstract Number: 1504 • ACR Convergence 2024
Novel Analytes Associated with Cognitive Impairment in Patients with Systemic Lupus Erythematosus: Serum S100A8/A9, MMP-9 and IL-6
Emma Neary¹, Carolina Munoz-Grajales², Joan Wither³, Juan Pablo Diaz Martinez³, Michelle Barraclough⁴, Kathleen Bingham³, Roberta Kretzmann³, Maria Carmela Tartaglia⁵, Lesley Ruttan⁶, May Choi⁷, Simone Appenzeller⁸, Sherief Marzouk³, Dennisse Bonilla³, Patti Katz⁹, Dorcas Beaton¹⁰, Robin Green³, Laura Patricia Whittall Garcia³, Dafna Gladman¹¹ and Zahi Touma¹², ¹McGill University, Montreal, QC, Canada, ²UHN/TWH, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴The University of Manchester, Manchester, United Kingdom, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Toronto Rehab/University Health Network - University Centre, Toronto, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸Unicamp, Campinas, SP, Brazil, ⁹UCSF, San Rafael, CA, ¹⁰Institute for Work & Health, Toronto, ON, Canada, ¹¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ¹²University of Toronto, Toronto, ON, Canada

Background/Purpose: Cognitive impairment (CI) is an increasingly prevalent neuropsychiatric manifestation in patients with systemic lupus erythematosus (SLE). Although CI has been identified through patient-reported outcomes…
Abstract Number: 1783 • ACR Convergence 2024
Deciphering the Roles of Mitochondrial-Related Genes and Ferroptosis in Systemic Lupus Erythematosus: Integrated Analysis for Diagnostic Biomarker Identification and Therapeutic Insights
Yunfeng Dai and Zhihan Chen, Fujian Medical University, Fuzhou City, Fujian, China (People's Republic)
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with heterogeneous clinical manifestations. Understanding the molecular mechanisms of SLE is crucial for developing effective…
Abstract Number: 2070 • ACR Convergence 2024
Increased Circulating Levels of Fatty Acid-binding Proteins as a Potential Biomarker of Disease Damage in Inflammatory Myopathies Patients
Margherita Giannini¹, Anne-Laure Charles², Julien Blaess³, Rose-Marie Javier⁴, Bernard Geny⁵ and Alain Meyer⁶, ¹UR3072, Physiology Department, University Hospital of Strasbourg, Strasbourg, France, ²UR3072, University of Strasbourg, Strasbourg, France, ³Physiology Department, University Hospital of Strasbourg, STRASBOURG, France, ⁴Rheumatology Department, University Hospital of Strasbourg, STRASBOURG, France, ⁵UR3072, Physiology Department, University Hospital of StrasbourgUniversity Hospital of Strasbourg, STRASBOURG, France, ⁶UR3072, Physiology Department, Rheumatology Department, University Hospital of Strasbourg, Strasbourg, France
Background/Purpose: In inflammatory myopathies (IM), although several treatments effectively control disease activity, a high proportion of patients display sustained disability (damage). Damage might be reversed…
Abstract Number: 2315 • ACR Convergence 2024
Exploring Antibodies in Psoriatic Arthritis: A Novel Autoimmune Biomarker Discovered
Theo WIRTH¹, Emmanuel Massy², Nathalie Lambert³, Isabelle Auger³, Nathalie Balandraud¹ and Florent Amatore⁴, ¹Department of Rheumatology, Sainte Marguerite Hospital, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, Marseille, France, ²Department of Rheumatology, Lyon Sud Hospital, Hospices Civils de Lyon, Lyon, France, ³INSERM UMRs1097, Arthrites autoimmunes, Marseille, Marseille, France, ⁴Department of Dermatology, Nord hospital, Assistance Publique des Hôpitaux de Marseille, Aix Marseille University, MARSEILLE 9EME, France
Background/Purpose: Psoriatic arthritis (PsA) can be challenging to diagnose due to the lack of specific biomarkers. Although a few teams have demonstrated the presence of…
Abstract Number: 2505 • ACR Convergence 2024
C5 Signaling Pathway Genes as Key Drivers of the Pathogenesis of IgA Vasculitis?
Joao Carlos Batista-Liz¹, Vanesa Calvo-Rio², María Sebastián Mora-Gil³, Ligia Gabrie-Rodriguez⁴, Rafael Gálvez Sánchez⁴, Belén Sevilla-Pérez⁵, José Luis Callejas⁶, María Teresa Leonardo⁷, Ana Peñalba⁷, Javier Narvaez-García⁸, Luis Martín-Penagos⁹, Luis Caminal-Montero¹⁰, PAZ COLLADO¹¹, Patricia Quiroga Colina¹², Esther Vicente-rabaneda¹³, Esteban Rubio¹⁴, Manuel León Luque¹⁵, Juan María Blanco-Madrigal¹⁶, Eva Galindez-Agirregoikoa¹⁷, Santos Castañeda¹³, Ricardo Blanco-Alonso¹⁸, Veronica Pulito-Cueto¹ and Raquel Lopez-mejias¹, ¹IDIVAL, Santander, Spain, ²Valdecilla Hospital, Santander, Cantabria, Spain, ³Immunopathology Group, IDIVAL, Santander, Spain, ⁴Immunopathology Group, IDIVAL. Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵Division of Pediatrics, Hospital Universitario San Cecilio, Granada, Spain, ⁶Systemic Autoimmune Diseases Unit, Hospital Clinico San Cecilio, Instituto de Investigación Biosanitaria de Granada ibs.GRANADA, Granada, Spain, ⁷Division of Pediatrics, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁸Hospital Universitario de Bellvitge, Barcelona, Spain, ⁹Immunopathology Group, IDIVAL. Division of Nephrology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ¹⁰Internal Medicine Department, Hospital Universitario Central de Asturias, Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain, ¹¹Hospital Universitario Severo Ochoa, MADRID, Spain, ¹²Division of Rheumatology, Hospital Universitario de La Princesa, Madrid, Spain, ¹³Hospital Universitario de La Princesa, Madrid, Spain, ¹⁴Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain, Sevilla, Spain, ¹⁵Division of Rheumatology, Hospital Universitario Virgen del Rocío, Sevilla, Spain., Sevilla, Spain, ¹⁶Division of Rheumatology, Hospital Universitario de Basurto, Bilbao, Spain., Bilbao, Spain, ¹⁷BASURTO UNIVERSITY HOSPITAL, BILBAO, Spain, ¹⁸Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Immunoglobulin A Vasculitis (IgAV) is an inflammatory disease caused by the accumulation of immune complexes of IgA in the walls of small blood vessels…
Abstract Number: 2689 • ACR Convergence 2024
Characterization of Alpha-1 Antitrypsin Function in ANCA-Associated Vasculitis
Lynn Fussner¹, Ivan Bilic², Carol McAlear³, David Cuthbertson⁴, Jie Cheng⁵, Elise Chen⁵, Markus Weiller², Ulrich Specks⁶ and Peter Merkel³, and for the Vasculitis Clinical Research Consortium, ¹The Ohio State University, Columbus, OH, ²Takeda Pharmaceuticals, Vienna, Austria, ³University of Pennsylvania, Philadelphia, PA, ⁴University of South Florida, Tampa, FL, ⁵Takeda Pharmaceuticals, Cambridge, MA, ⁶Mayo Clinic, Rochester, MN
Background/Purpose: Two separate genome-wide association studies demonstrated that polymorphisms in SERPINA1, encoding serine protease inhibitor alpha-1 antitrypsin (A1AT), are associated with increased risk of developing…
Abstract Number: 0075 • ACR Convergence 2024
Micro-RNAs as Biomarkers for Methotrexate Treatment Response in Patients with Psoriatic Arthritis
Darshini Ganatra¹, Omar Cruz Correa¹, Ameth Garrido², Starlee Lively³, Rohan Apurva Machhar⁴, Remy Pollock⁵, Mohit Kapoor⁶ and Dafna Gladman⁷, ¹University Health Network, Toronto, ON, Canada, ²University of Toronto, Toronto, ON, Canada, ³UHN, Toronto, Canada, ⁴Novartis, Mississauga, ON, Canada, ⁵Pfizer, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, University Health Network, Toronto, ON, Canada, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is a form of inflammatory arthritis linked to psoriasis, a chronic skin and nail disease. PsA is a progressive joint disease…
Abstract Number: 0424 • ACR Convergence 2024
The Clinical Utility of Serum BAFF Levels in Pregnant Patients with SLE
Catherine Sims¹, Amanda Eudy², Samir Soneji³, Kateena Addae-Konadu³, Jennifer Gilner³, Andra James³, Jerome Federspiel⁴, Eugene Kovalik³, Anika Lucas⁴, Laura Neil⁵, Amanda Snyderman³ and Megan Clowse⁶, ¹Duke University, Knightdale, NC, ²Duke University, Raleigh, NC, ³Duke University School of Medicine, Durham, ⁴Duke University School of Medicine, Durham, NC, ⁵Duke University, Durham, ⁶Duke University, Chapel Hill, NC
Background/Purpose: The B cell Activating Factor (BAFF) signaling pathway plays an important role in the selection, maturation, and survival of B cells; it consequently contributes…
Abstract Number: 0565 • ACR Convergence 2024
Low Vitamin D Serum Level Is a Risk Factor for Ankylosis in Axial Spondyloarthritis: Evidence from a Nested-Case-Control Study
Anthony Lichaa¹, Pauline KRUG¹ and Adrien Nzeusseu Toukap², ¹Cliniques universitaires St-Luc, Brussel, Belgium, ²Cliniques universitaires Saint-Luc,, St.-Lambrechts-Woluwe, Belgium
Background/Purpose: Axial spondyloarthritis (axSpA) is a progressive disease, characterized by chronic inflammation and progressive structural damage. However, the kinetic of progression to ankylosis and much…
Abstract Number: 0694 • ACR Convergence 2024
A Unified Vascular Phenotype Score Identifies Systemic Sclerosis Endotypes and Predicts Prognostic Outcomes: Results from the EUSTAR Database
Stefano Di Donato¹, Michael Hughes², John Pauling³, Marco Matucci-Cerinic⁴, Lesley-Anne Bissell⁵, Edward Jude⁶, Christopher Denton⁷, Yannick Allanore⁸, Marie-Elise Truchetet⁹ and Francesco Del Galdo¹⁰, and EUSTAR collaborators, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Leeds, UK, Leeds, United Kingdom, ²Tameside and Glossop Integrated NHS Foundation Trust & The University of Manchester, Manchester, United Kingdom, ³North Bristol NHS Trust, Bristol, United Kingdom, ⁴University San Raffaele Milano, Milano, Milan, Italy, ⁵Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁶Tameside and Glossop Integrated Care NHS Foundation Trust, Ashton-under-Lyne, United Kingdom, ⁷University College London, Northwood, United Kingdom, ⁸Université Paris Cité, Paris, France, ⁹Bordeaux University Hospital, Bordeaux, France, ¹⁰University of Leeds, Leeds, United Kingdom
Background/Purpose: Vascular dysfunction is pivotal in Systemic Sclerosis (SSc) pathogenesis, leading to somatic vascular signs such as pitting scars, Digital Ulcers (DUs), telangiectasia as well…
Abstract Number: 0814 • ACR Convergence 2024
Rare Variants of PAH Risk Genes Associate with a Distinct Vasculopathy Phenotype and Worse Outcomes in Patients with Systemic Lupus Erythematosus-associated Pulmonary Arterial Hypertension
Junyan Qian¹, Xinzhuang Yang², Yu Fang Ding³, qian wang¹, Jiuliang Zhao¹, Weida Liu⁴, Yongtai Liu⁵, Zhuang Tian⁵, Yanhong Wang⁶, Xiaojian Wang⁷, Mengtao Li¹ and Xiaofeng Zeng⁸, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, Beijing, China, ²Center for Bioinformatics, National Infrastructures for Translational Medicine, Institute of Clinical Medicine & Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ³Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China 2National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology, BEIJING, China (People's Republic), ⁴State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, ⁵Department of Cardiology, Peking Union Medical College Hospital, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing, China, ⁶Department of Epidemiology and Biostatistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, ⁷State Key Laboratory of Cardiovascular Disease, Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China, ⁸Department of Rheumatology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Beijing, China
Background/Purpose: Systemic lupus erythematosus (SLE)-associated pulmonary arterial hypertension (PAH) displays significant clinical heterogeneity; nevertheless, the underlying mechanisms remain unclear. Presently, more than twenty risk genes…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].